The Association between (Serum prostatic specific antigen and Dihydrotestosterone) and Efficacy of Solifenacin Therapy for Benign prostatic hypertrophy Patient in Salahalddin Society

Abstract

Background:     Benign   prostatic   hypertrophy   (BPH)   is  a  condition   in  which   the prostate  becomes  enlarged  as part  of the  aging  process.  BPH  Primarily  affects  men over the  age of 40, of all races  and ethnic backgrounds.  No  one knows  specifically why an enlarged prostate  occurs.  However,  hormones  and genetics  may play a role in the condition's  development  some researchers  believe that  it may be related to a drop in testosterone  levels as men age. Others believe that  one enlarged prostate cause is the reawakening  of cells that deliver signals to other cells in the prostate.
Objective: To evaluate the relation between serum prostatic specific antigen (PSA) and dihydrotestosterone (DHT) on the effects of 4 weeks of solifenacin therapy for BPH patients.
Patients and Methods: A total of 108 patients attending the consultation department at Tikrit teaching hospital were enrolled in this case control study during the period from Novemberl®, 2011 tol™ of August, 2012. All patients had BPH with al- blocker treatment during the study period, a change in type and dosage of al-blocker was not allowed, Solifenacin (Smg) once daily dose was administered to the patients for 4 weeks.
PSA  level,  serum DHT,  IPSS,  post voiding  residual  PVR,  and prostatic  size were measured  before and after treatment.  The patients  themselves  serve as their own control group. Estimation  of Serum DHT and serum PSA using Elisa kit.

Results: The relationship between PSA level and prostate size is probably the most natural reason for the correlation of urinary symptoms and serum PSA level .also found age and Higher serum DHT concentration were associated with larger prostate volume, elevate PSA level, less response to solifenacin. In the present study, strong direct and significant relationship found between storage symptom, voiding symptom and total IPSS with DHT level for men who treated with solifenacin +a- blocker than men who take a-blocker alone. While clarified non-significant differences found between PVR and the use of solifenacin +a-blocker and prostate size.
Conclusion:     Serum PSA and DHT can be used to predict effect of solifenacin  on BPH after al-blockers   monotherapy.